Irhythm Technologies Stock Forecast, Price & News

Irhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRTC shares have increased by 162.6% and is now trading at $224.64.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Irhythm Technologies.

Irhythm Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Irhythm Technologies.

Irhythm Technologies will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Irhythm Technologies Inc (NASDAQ:IRTC) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.09. The business had revenue of $50.88 million for the quarter, compared to the consensus estimate of $42.18 million. Irhythm Technologies had a negative net margin of 28.50% and a negative return on equity of 50.23%. The business's revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.43) EPS.
View Irhythm Technologies' earnings history.

12 equities research analysts have issued twelve-month price targets for Irhythm Technologies' shares. Their forecasts range from $130.00 to $250.00. On average, they anticipate Irhythm Technologies' stock price to reach $186.44 in the next twelve months. This suggests that the stock has a possible downside of 17.0%.
View analysts' price targets for Irhythm Technologies.

Some companies that are related to Irhythm Technologies include FRESENIUS SE &/S (FSNUY), Insulet (PODD), Teleflex (TFX), ABIOMED (ABMD), Novocure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Haemonetics (HAE), Nevro (NVRO), Globus Medical (GMED), Integra LifeSciences (IART), ICU Medical (ICUI), Inspire Medical Systems (INSP) and Inari Medical (NARI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and The Boeing (BA).

(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Alberta Investment Management Corp (0.22%), CWM LLC (0.09%), Envestnet Asset Management Inc. (0.04%), Spearhead Capital Advisors LLC (0.01%), Altium Wealth Management LLC (0.00%) and Mitchell Sinkler & Starr PA (0.00%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Mark J Day, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, and Arden Trust Co. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Mark J Day, Matthew C Garrett, Ralph Snyderman, and Raymond W Scott.
View insider buying and selling activity for Irhythm Technologies.

IRTC stock was bought by a variety of institutional investors in the last quarter, including Alberta Investment Management Corp, Altium Wealth Management LLC, Mitchell Sinkler & Starr PA, Fieldpoint Private Securities LLC, Fulton Bank N. A., Abbot Financial Management Inc., Nisa Investment Advisors LLC, and Envestnet Asset Management Inc..
View insider buying and selling activity for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $224.64.

Irhythm Technologies has a market capitalization of $6.48 billion and generates $214.55 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.

The official website for Irhythm Technologies is www.irhythmtech.com.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]